Wockhardt Limited (NSE:WOCKPHARMA)
1,360.00
+28.10 (2.11%)
At close: Dec 5, 2025
Wockhardt Revenue
Wockhardt had revenue of 7.82B INR in the quarter ending September 30, 2025, a decrease of -3.34%. This brings the company's revenue in the last twelve months to 30.07B, up 0.87% year-over-year. In the fiscal year ending March 31, 2025, Wockhardt had annual revenue of 30.35B with 7.24% growth.
Revenue (ttm)
30.07B
Revenue Growth
+0.87%
P/S Ratio
7.35
Revenue / Employee
13.10M
Employees
2,296
Market Cap
220.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 30.35B | 2.05B | 7.24% |
| Mar 31, 2024 | 28.30B | 1.73B | 6.51% |
| Mar 31, 2023 | 26.57B | -5.73B | -17.74% |
| Mar 31, 2022 | 32.30B | 5.22B | 19.28% |
| Mar 31, 2021 | 27.08B | -1.36B | -4.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Wockhardt News
- 5 days ago - Wockhardt shares rally sharply over 9% as US FDA accepts NDA for breakthrough antibiotic Zaynich - Business Upturn
- 5 days ago - Wockhardt secures historic US FDA acceptance for antibiotic Zaynich - Business Upturn
- 2 months ago - Wockhardt submits NDA to US FDA for novel antibacterial Zidebactam-Cefepime - Business Upturn
- 2 months ago - Wockhardt shares fall over 5% after Trump’s pharma tariff announcement - Business Upturn
- 3 months ago - Shukra Pharmaceuticals secures Pan-India distribution rights from Wockhardt - Business Upturn
- 4 months ago - Wockhardt Q1 Results: Shares drop 3% as EBITDA falls 20.9% YoY Rs 72 crore, revenue flat at Rs 739 - Business Upturn
- 5 months ago - Wockhardt shares jump 4% after exiting loss-making US generics business - Business Upturn
- 5 months ago - Wockhardt exits US generics business to focus on innovative portfolio - Business Upturn